ArticleOpen forum infectious diseases2015
Epidemiology and Outcome of Trichosporon Fungemia: A Review of 185 Reported Cases From 1975 to 2014.
Article in Open forum infectious diseases, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 98 citations in OpenAlex.
- Epidemiological study ofEpidemiology and infection · 2020Pooled it
- Trichosporon fungemia in critically ill patients: A case series.Journal of postgraduate medicine · 2026Article
- Comparison of two MALDI-TOF MS platforms for identification of Trichosporon isolates from patients in a tertiary hospital in Hefei, China.BMC infectious diseases · 2026Article
- Ferrous sulfate induces ferroptosis-like cell death inFrontiers in microbiology · 2026Article
- Clinical Manifestations of Emerging Trichosporon spp. Infections, France.Emerging infectious diseases · 2026Article
- Cryptococcal antigen cross-reactivity is associated with fatal trichosporonosis in patients with hematologic diseases.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Article
- Invasive trichosporonosis in children: a 10-year experience from a tertiary care center in Türkiye.Journal of tropical pediatrics · 2025Article
- Trichosporon species bloodstream infections in a tertiary care hospital in the western region of Saudi Arabia: A 7-year retrospective chart review from 2016 to 2022.Medical mycology · 2025Article
- Review
- Navigating Trichosporon Asahii Infections in Pediatric Leukemia: First Reported Case in Central and Eastern Europe Case Report and Literature Review.Infection and drug resistance · 2025Article
- The Prevalence and Risk Factors of Trichosporonosis at King Abdulaziz University Hospital.International journal of general medicine · 2024Article
- A novel report on the emerging and zoonotic neurotropic fungus Trichosporon japonicum in the brain tissue of the endangered Brazilian guitarfish (Pseudobatos horkelii) off the southeastern coast of Brazil.BMC microbiology · 2023Article
- Antifungal Activity and Potential Action Mechanism of Allicin against Trichosporon asahii.Microbiology spectrum · 2023Article
- Antifungal Drug Resistance: An Emergent Health Threat.Biomedicines · 2023Review
- Mycotic aneurysms due toIDCases · 2023Article
- Spectrum of signs, symptoms, and treatment in amphotericin B-resistantIndian journal of ophthalmology · 2022Article
- EQUAL Trichosporon Score 2022: an ECMM score to measure QUALity of the clinical management of invasive Trichosporon infections.The Journal of antimicrobial chemotherapy · 2022Review
- Factors Associated with Breakthrough Fungemia Caused byAntimicrobial agents and chemotherapy · 2022Article
- COVID-19-associated brain abscess caused byMedical mycology case reports · 2022Article
- Invasive Trichosporonosis in Neonates and Pediatric Patients with Malignancies or Hematologic Disorders.Pathogens (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background. Trichosporon species have emerged as an important non-Candida spp yeast pathogen in immunocompromised patients in recent decades; however, the systemic analysis of Trichosporon epidemiology has seldom been reported. Methods. We reviewed 185 reported cases of Trichosporon fungemia from 1975 to 2014 in the English-language literature, and the epidemiology and prognostic factors of the included cases are described. Results. The number of cases reported has increased with time, especially over the past decade. During the 3 decades from 1975 to 2004, the most commonly used antifungal compounds were amphotericin B/liposomal amphotericin B; however, in recent decades (2005-2014), triazoles (especially voriconazole) have become the most widely used agents, significantly improving outcome in the reported cases. Correlation analysis revealed that negative outcome is associated with several prognostic factors, including a history of antimicrobial use, bacterial bloodstream coinfection, prophylactic/empirical antifungal therapy, Trichosporon beigelii infection, and receiving the antifungal regimen of amphotericin B/liposomal amphotericin B. In addition, a significantly greater proportion of patients with a positive outcome had fungemia without invasive tissue infection and received a voriconazole regimen or an AmB-triazole combined regimen. Significant positive outcome was also associated with patients who had recovered from neutropenia or after central venous catheter removal. Conclusions. Voriconazole can be recommended as a first-line antifungal compound to treat Trichosporon fungemia; the immune status of the host plays a crucial role in the outcome of this infection, and the removal of vascular catheters should be considered if feasible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.